Compare Atomera Incorporated (ATOM) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs Cronos Group Inc — how do they compare? Atomera Incorporated trades at $6.48 (market cap $247.40M), while Cronos Group Inc trades at $2.74 (market cap $1.02B). The key difference: Cronos Group Inc is far larger — about 4.1× Atomera Incorporated's market cap, and Cronos Group Inc is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ATOM | CRON | |
|---|---|---|
Market Cap | $247.40M | $1.02B |
Sector | Technology | Health |
52-Week High | $12.11 | $3.27 |
52-Week Low | $1.99 | $1.95 |
Enterprise Value | $207.61M | $203.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $6.25, down 5.73% over 24 hours, reflecting a bearish technical outlook with negative earnings trends. The company reported a net loss of $20.17 million in 2025 on minimal revenue of $65,000, with profitability metrics deeply negative. Recent news highlights Atomera's focus on semiconductor technology advancements, including GaN-on-Silicon collaborations, but financial performance remains a significant concern.
The outlook is cautious due to persistent losses and weak revenue, though analyst consensus is unanimously bullish with a 100% buy rating. Key risks include execution challenges in monetizing technology and high cash burn. Upside depends on successful commercialization of its semiconductor IP, but current fundamentals suggest high volatility and substantial shareholder risk.
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
